Robins Sander J
Framingham Heart Study, 73 Mt. Wayte Avenue, Framingham, MA 01702, USA.
Curr Cardiol Rep. 2005 Nov;7(6):457-64. doi: 10.1007/s11886-005-0064-9.
Insulin resistance with the development of diabetes or metabolic syndrome is associated with characteristic lipid abnormalities and an increased likelihood of cardiovascular events. This review examines the rationale and clinical trial evidence for the benefit of lipid drug therapy in the presence of these related high-risk conditions. In particular, the results of the more recent statin trials are discussed and contrasted with evidence from trials with fibrates, which, although fewer in number, appear to show that this particular therapy has selective benefit for the overweight individual with diabetes or features of the metabolic syndrome.
胰岛素抵抗伴发糖尿病或代谢综合征时，会出现特征性脂质异常，心血管事件发生风险也会增加。本综述探讨了在这些相关高危情况下进行脂质药物治疗获益的理论依据和临床试验证据。特别讨论了近期他汀类药物试验的结果，并与贝特类药物试验的证据进行对比，贝特类药物试验数量较少，但似乎表明这种特殊治疗对患有糖尿病或具有代谢综合征特征的超重个体有选择性益处。
